Lincoln Pharmaceuticals is currently trading at Rs. 247.80, up by 11.10 points or 4.69% from its previous closing of Rs. 236.70 on the BSE.
The scrip opened at Rs. 238.00 and has touched a high and low of Rs. 247.85 and Rs. 238.00 respectively. So far 83670 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 304.80 on 06-Jan-2016 and a 52 week low of Rs. 128.00 on 26-May-2016.
Last one week high and low of the scrip stood at Rs. 247.85 and Rs. 228.15 respectively. The current market cap of the company is Rs. 403.69 crore.
The promoters holding in the company stood at 35.81%, while institutions and non-institutions held 1.93% and 62.26% respectively.
Lincoln Pharmaceuticals has unveiled an Ondansetron oral spray, used for treatment of nausea and vomiting caused by surgery or cancer drugs, in the Indian market. The company has done bio-equivalent study for Ondansetron oral spray and has got the Drug Controller General of India (DCGI) permission. Ondansetron was earlier available as tablet, syrup and injectable in India. All India level the Anti-emetic drug market is Rs 678 crore and Ondansetron is one of the anti-emetic drug and all over India market is Rs 303 crore. Therefore, Ondansetron Spray is having very good market opportunity.
Lincoln Pharmaceuticals is a company is based at Ahmedabad and engaged in Manufacturing and Export of Pharmaceuticals formulations under various Therapeutic product group, plant duly complied with WHO-GMP guidelines. The Company is exporting more than 45 countries along with Domestic market in more than 20 states in India.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |